Psyence BioMed Posts $1.94M H1 Loss, $21.1M Cash; PsyLabs Stake Hits 43.4%
PBM sits 35% above its 52-week low of $1.92.
Summary
Psyence BioMed reported a $1.94M net loss for the six months to September 30 with $21.1M of cash after raising $16.9M through its equity line, and disclosed that October transactions lifted its PsyLabs stake to roughly 43.4%.
Key Events · Earnings and Guidance · PBM
-
H1 Net Loss of $1.94M
Net loss for the six months ended September 30, 2026 was $1,937,058 versus $1,992,732 a year earlier; loss per share was $0.53 against $11.76.
-
Cash Jumps to $21.1M on ELOC Sales
Cash and equivalents including restricted cash reached $21,140,337 from $7,491,954 at March 31, after issuing 1,519,383 shares under the ELOC for $16,931,511 gross; $61,836,722 remains available under the $100M facility.
-
Share Count Up Sharply
Shares outstanding rose from 2,293,277 at March 31 to 3,816,548 at September 30 and 5,318,218 as of the MD&A date, reflecting ELOC sales, the October share swap and RSU exercises.
-
PsyLabs Stake Reaches 43.4%
The October 1 share-for-share swap (1,497,500 shares at a deemed $6.00, $8,985,000 agreed value) plus the October 16 backstop subscription of $2,599,896 lifted the PsyLabs holding to 11,565 shares, about 43.37%.
Analysis · PBM · Life Sciences
The balance sheet has been transformed by the equity line: cash and equivalents stood at $21.1M on September 30 versus $7.4M six months earlier, funded by 1.5M shares sold under the ELOC for $16.9M. That works out to roughly a 66% increase in the share count over six months (1,519,383 issued against 2,293,277 outstanding at March 31), and the count has since climbed to 5,318,218 as of the MD&A date — dilution is the price of the runway. The loss itself is modest at $1.94M for the half, and operating cash burn was only $0.39M, so the money is flowing into PsyLabs rather than overhead: $2.99M of cash went into the associate during the period, and the October share-for-share swap (1,497,500 shares at a deemed $6.00) plus the $2.6M backstop take-up lifted the stake to about 43.4%. In effect, the company is converting its own equity into a controlling-scale position in its supplier — the strategic bet investors are underwriting.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBM was trading at $2.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $1.92 to $18.31. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.